Adenoma Detection Rate With Endocuff-Assisted Colonoscopy - an Italian Trial (ITAvision)
Primary Purpose
Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Standard colonoscopy
ARC Endocuff Vision
Sponsored by
About this trial
This is an interventional screening trial for Colorectal Cancer focused on measuring Mass screening, Adenoma detection rate, ARC Endocuff Vision, Colonoscopy
Eligibility Criteria
Inclusion Criteria:
- Subject with a positive FIT result in the frame of national screening program
Exclusion Criteria:
- Subjects younger than 50 years old
- Active Inflammatory Bowel Disease
- Known condition of cholic stenosis
- Acute diverticulitis
- Patient not able to sign a informed consent form
Sites / Locations
- Santa Maria del Prato, Local Health Unit 1 Dolomiti, Veneto Region
- San Martino Hospital, Local Health Unit 1 Dolomiti, Veneto Region
- Maggiore Hospital, Crema Territorial Health Care Company, Lombardia RegionRecruiting
- Cazzavillan Hospital, Local Health Unit 8 Berica, Veneto Region
- Screening Unit, Oncological Network, Prevention and Research InstituteRecruiting
- San Paolo Hospital Company - University Campus
- Sant'Antonio Hospital, Local Health Unit 6 Euganea, Veneto Region
- Veneto Tumor Registry, Local Health Unit 4, Veneto Region
- Santa Maria della Misericordia Hospital, Local Health Unit 5 Polesana, Veneto Region
- Ca' Foncello Hospital, Local Health Unit 2 Marca Trevigiana, Veneto Region
- Molinette Hospital, Città della Salute e della Scienza University Hospital Company
- San Bonifacio Hospital, Local Health Unit 9 Scaligera, Veneto Region
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard colonoscopy (S)
AEV assisted colonoscopy (E)
Arm Description
A standard colonoscopy will be performed.
Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
Outcomes
Primary Outcome Measures
Adenoma Detection Rate (ADR)
Comparison of the number of adenomas (ADR) detected per subject between the Endocuff Vision colonoscopy and the standard colonoscopy.
Secondary Outcome Measures
Patient values
Comparison of ADR according to patient's age, sex, screening history (first or subsequent test) between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Exam values
Comparison of cecum intubation, patient discomfort (with Visual Analogue Scale -VAS) between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
The Visual Analogue Scale goes from 1 to 10, where 1 is the absence pain and 10 is severe pain.
Number 1 represents the best outcome measure, while 10 is the worst result for this outcome measure.
Number of lesions
Comparison of polyps number between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Size
Comparison of polyps size between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Anatomical site
Comparison of polyps anatomical site between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Histological diagnoses
Comparison of polyps histological diagnoses between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Colonoscopist' age
Analysis of the involved colonoscopists' age.
Colonoscopist' years of experience
Analysis of the involved colonoscopists' years of experience.
Colonoscopist' specialization
Analysis of the involved colonoscopists' specialization.
Colonoscopist' number of exams in the previous year
Analysis of the involved colonoscopists' number of exams in the previous year.
Colonoscopists' ADR in the previous year
Analysis of the involved colonoscopists' ADR in the previous year.
Full Information
NCT ID
NCT03612674
First Posted
July 2, 2018
Last Updated
July 27, 2018
Sponsor
Cancer Prevention and Research Institute, Italy
Collaborators
Veneto Tumor Registry, Azienda Zero, Padua, Italy
1. Study Identification
Unique Protocol Identification Number
NCT03612674
Brief Title
Adenoma Detection Rate With Endocuff-Assisted Colonoscopy - an Italian Trial
Acronym
ITAvision
Official Title
Adenoma Detection Rate With ARC Endocuff Vision Assisted Colonoscopy vs. Standard Colonoscopy in Colorectal Cancer Screening: a Multicenter Randomized Italian Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 4, 2018 (Actual)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
August 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cancer Prevention and Research Institute, Italy
Collaborators
Veneto Tumor Registry, Azienda Zero, Padua, Italy
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In European countries, colorectal cancer (CRC) represents an important public health problem. It is widely held view that most carcinomas develop from an adenoma-carcinoma progression.
Adenoma detection rate (ADR) is a marker of high quality colonoscopy and it was inversely associated with the risk of interval colorectal cancer, advanced-stage interval cancer, and fatal interval cancer after colonoscopy.
Although colonoscopy is considered the gold standard for adenoma detection, it has shown some limits, so industry has aimed at increasing detection rate of adenomas providing new technologies, most of witch to detect lesions located in blind spots.
ARC Endocuff Vision (AEV), the second generation of Endocuff, represents a new generation of these devices, thus assessing the diagnostic sensibility of ARC Endocuff Vision assisted colonoscopy (EAC) is an interesting challenge.
Aim of the study is to compare ADR of EAC versus standard colonoscopy among FIT positive subjects in the context of CRC screening programs.
Detailed Description
In European countries, colorectal cancer (CRC) represents an important public health problem. It is widely held view that most carcinomas develop from an adenoma-carcinoma progression.
It has been demonstrated that screening with fecal occult blood test (FOBT) significantly reduces mortality for CRC. Currently, population-based CRC screening programs using FOBT have been or are heading towards being implemented in many European countries. Fecal immunochemical test (FIT) has been adopted by most Italian Regions as the standard screening test, with total colonoscopy as diagnostic assessment in subjects resulted FIT positive. A significant impact of FIT-based screening on CRC mortality reduction has been observed in an Italian region after 10 years from screening implementation. Moreover, two studies carried out in a Northern-central area of Italy have shown a reduction in CRC incidence in subjects who attended FIT screening programs as compared to non-attendees.
Increasing colonoscopy quality is critical for the screening impact among population. Adenoma detection rate (ADR) is a marker of high quality colonoscopy and it was inversely associated with the risk of interval colorectal cancer, advanced-stage interval cancer, and fatal interval cancer after colonoscopy. ADR is defined as the proportion of colonoscopies during which at least one adenoma can be detected. A polish study showed that ADR was an independent predictor of the risk of interval colorectal cancer after screening colonoscopy. ADR has shown a direct correlation with: operator experience, cecal intubation, quality of bowel preparation, patient sedation, endoscope withdrawal time, presence of flat, depressed or subtle lesions, ability to visualize the proximal side of haustral folds, flexures (blind spots), rectal valves, and ileocecal valves.
On the other hand, colonoscopy is considered the gold standard for adenoma detection, but it has shown some limits. Data from colonoscopy studies showed that up to 25% of polyps were missed during colonoscopy and up to 8% of CRCs occurred within 3 years after a previous colonoscopy. Moreover, recent studies have shown that cancers post-colonoscopy are most likely due to missed lesions, rather than being new lesions.
For these reasons, industry has aimed at increasing detection rate of adenomas providing new technologies, most of witch to detect lesions located in blind spots.
ARC Endocuff Vision (AEV), the second generation of Endocuff, represents a new generation of these devices, thus assessing the diagnostic sensibility of ARC Endocuff Vision assisted colonoscopy (EAC) is an interesting challenge.
Previous researches have studied the performance of colonoscope distal attachment devices. More specifically, a 2016 meta-analysis of more than 5,000 patients demonstrates that, compared to traditional colonoscopy, the use of an Endocuff device improves ADR without any adverse effect on procedural efficiency or increased risk of significant adverse events. Moreover, Facciorusso et al. in 2017 assessed only a modest improvement in ADR by using distal attachment devices, especially in low-performing endoscopists, while in 2018 Williet showed, with moderate-quality evidence, an improvement in ADR with EAC without major adverse events, especially for operators with low-to-moderate ADR.
Second-generation AEV is a soft plastic cap, to be applied on the top of the colonoscopy. The cap has a propylene-made cylindrical core, with a single row of flexible arms. During the colon intubation procedure the device is nearly invisible, while in the retraction phase the arms begin to work, opening up and pulling the colon walls, stretching convoluted tracts.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Colorectal Adenoma, Colorectal Polyp, Colorectal Neoplasms
Keywords
Mass screening, Adenoma detection rate, ARC Endocuff Vision, Colonoscopy
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects will be randomized in two arms: a control-arm and an experimental-arm. Then arms data will be compared.
Masking
Participant
Masking Description
Participants will not be informed about diagnostic procedure in order to evaluate the acceptability of the exam with or without the studied device (in fact at the end of the examination care provider will ask participant about perceived pain during the procedure through the VAS score).
Allocation
Randomized
Enrollment
2100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard colonoscopy (S)
Arm Type
Active Comparator
Arm Description
A standard colonoscopy will be performed.
Arm Title
AEV assisted colonoscopy (E)
Arm Type
Experimental
Arm Description
Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
Intervention Type
Procedure
Intervention Name(s)
Standard colonoscopy
Intervention Description
Current standard of care colonoscopy.
Intervention Type
Device
Intervention Name(s)
ARC Endocuff Vision
Intervention Description
Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
Primary Outcome Measure Information:
Title
Adenoma Detection Rate (ADR)
Description
Comparison of the number of adenomas (ADR) detected per subject between the Endocuff Vision colonoscopy and the standard colonoscopy.
Time Frame
Through study completion, an average of 1 year
Secondary Outcome Measure Information:
Title
Patient values
Description
Comparison of ADR according to patient's age, sex, screening history (first or subsequent test) between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Time Frame
Day 1
Title
Exam values
Description
Comparison of cecum intubation, patient discomfort (with Visual Analogue Scale -VAS) between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
The Visual Analogue Scale goes from 1 to 10, where 1 is the absence pain and 10 is severe pain.
Number 1 represents the best outcome measure, while 10 is the worst result for this outcome measure.
Time Frame
Day 1
Title
Number of lesions
Description
Comparison of polyps number between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Time Frame
Day 1
Title
Size
Description
Comparison of polyps size between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Time Frame
Day 1
Title
Anatomical site
Description
Comparison of polyps anatomical site between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Time Frame
Day 1
Title
Histological diagnoses
Description
Comparison of polyps histological diagnoses between the standard colonoscopy arm and the Endocuff Vision colonoscopy arm.
Time Frame
Through study completion, an average of 1 year
Title
Colonoscopist' age
Description
Analysis of the involved colonoscopists' age.
Time Frame
Through study completion, an average of 1 year
Title
Colonoscopist' years of experience
Description
Analysis of the involved colonoscopists' years of experience.
Time Frame
Through study completion, an average of 1 year
Title
Colonoscopist' specialization
Description
Analysis of the involved colonoscopists' specialization.
Time Frame
Through study completion, an average of 1 year
Title
Colonoscopist' number of exams in the previous year
Description
Analysis of the involved colonoscopists' number of exams in the previous year.
Time Frame
Through study completion, an average of 1 year
Title
Colonoscopists' ADR in the previous year
Description
Analysis of the involved colonoscopists' ADR in the previous year.
Time Frame
Through study completion, an average of 1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject with a positive FIT result in the frame of national screening program
Exclusion Criteria:
Subjects younger than 50 years old
Active Inflammatory Bowel Disease
Known condition of cholic stenosis
Acute diverticulitis
Patient not able to sign a informed consent form
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Grazia Grazzini, MD
Phone
003905532697972
Email
g.grazzini@ispro.toscana.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gianni Amunni, MD
Organizational Affiliation
Oncological Network, Prevention and Research Institute
Official's Role
Study Director
Facility Information:
Facility Name
Santa Maria del Prato, Local Health Unit 1 Dolomiti, Veneto Region
City
Feltre
State/Province
Belluno
ZIP/Postal Code
32032
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Flavio Valiante, MD
Email
flavio.valiante@aulss1.veneto.it
Facility Name
San Martino Hospital, Local Health Unit 1 Dolomiti, Veneto Region
City
Belluno
State/Province
BL
ZIP/Postal Code
32100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bastianello Germanà, MD
Email
bastianello.germana@aulss1.veneto.it
Facility Name
Maggiore Hospital, Crema Territorial Health Care Company, Lombardia Region
City
Crema
State/Province
Cremona
ZIP/Postal Code
26013
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisabetta Buscarini, MD
Email
elisabetta.buscarini@asst-crema.it
Facility Name
Cazzavillan Hospital, Local Health Unit 8 Berica, Veneto Region
City
Arzignano
State/Province
Vicenza
ZIP/Postal Code
36071
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maurizio Pantalena, MD
Email
maurizio.pantalena@aulss8.veneto.it
Facility Name
Screening Unit, Oncological Network, Prevention and Research Institute
City
Florence
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grazia Grazzini, MD
Email
g.grazzini@ispro.toscana.it
Facility Name
San Paolo Hospital Company - University Campus
City
Milan
ZIP/Postal Code
20142
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carmelo Luigiano, MD
Email
carmelo.luigiano@ao-sanpaolo.it
Facility Name
Sant'Antonio Hospital, Local Health Unit 6 Euganea, Veneto Region
City
Padova
ZIP/Postal Code
35127
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erik Rosa Rizzotto, MD
Email
erik.rosarizzotto@aulss6.veneto.it
Facility Name
Veneto Tumor Registry, Local Health Unit 4, Veneto Region
City
Padova
ZIP/Postal Code
35131
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Santa Maria della Misericordia Hospital, Local Health Unit 5 Polesana, Veneto Region
City
Rovigo
ZIP/Postal Code
45100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Del Favero, MD
Email
giuseppe.delfavero@aulss5.veneto.it
Facility Name
Ca' Foncello Hospital, Local Health Unit 2 Marca Trevigiana, Veneto Region
City
Treviso
ZIP/Postal Code
31100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helena Salvat, MD
Email
helenaheras.salvat@aulss2.veneto.it
Facility Name
Molinette Hospital, Città della Salute e della Scienza University Hospital Company
City
Turin
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arrigo Arrigoni, MD
Email
aarrigoni@cittadellasalute.to.it
Facility Name
San Bonifacio Hospital, Local Health Unit 9 Scaligera, Veneto Region
City
Verona
ZIP/Postal Code
37047
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gianmarco Bulighin, MD
Email
gianmarco.bulighin@aulss9.veneto.it
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25227521
Citation
Zorzi M, Senore C, Da Re F, Barca A, Bonelli LA, Cannizzaro R, Fasoli R, Di Furia L, Di Giulio E, Mantellini P, Naldoni C, Sassatelli R, Rex D, Hassan C, Zappa M; Equipe Working Group. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy). Gut. 2015 Sep;64(9):1389-96. doi: 10.1136/gutjnl-2014-307954. Epub 2014 Sep 16.
Results Reference
background
PubMed Identifier
26303133
Citation
Giorgi Rossi P, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, Mangone L, Pezzarossi A, Roncaglia F, Campari C, Sassatelli R, Sacchero R, Sereni G, Paterlini L, Zappa M. Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. Am J Gastroenterol. 2015 Sep;110(9):1359-66. doi: 10.1038/ajg.2015.240. Epub 2015 Aug 25.
Results Reference
background
PubMed Identifier
24693890
Citation
Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, Quinn VP, Ghai NR, Levin TR, Quesenberry CP. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 3;370(14):1298-306. doi: 10.1056/NEJMoa1309086.
Results Reference
background
PubMed Identifier
20463339
Citation
Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010 May 13;362(19):1795-803. doi: 10.1056/NEJMoa0907667.
Results Reference
background
PubMed Identifier
22341103
Citation
Munroe CA, Lee P, Copland A, Wu KK, Kaltenbach T, Soetikno RM, Friedland S. A tandem colonoscopy study of adenoma miss rates during endoscopic training: a venture into uncharted territory. Gastrointest Endosc. 2012 Mar;75(3):561-7. doi: 10.1016/j.gie.2011.11.037.
Results Reference
background
PubMed Identifier
22104756
Citation
Faiss S. The missed colorectal cancer problem. Dig Dis. 2011;29 Suppl 1:60-3. doi: 10.1159/000331119. Epub 2011 Nov 15.
Results Reference
background
PubMed Identifier
24410471
Citation
Rees CJ, Rajasekhar PT, Rutter MD, Dekker E. Quality in colonoscopy: European perspectives and practice. Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):29-47. doi: 10.1586/17474124.2014.858599. Epub 2013 Dec 2.
Results Reference
background
PubMed Identifier
16454841
Citation
van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006 Feb;101(2):343-50. doi: 10.1111/j.1572-0241.2006.00390.x.
Results Reference
background
PubMed Identifier
22441756
Citation
Leufkens AM, van Oijen MG, Vleggaar FP, Siersema PD. Factors influencing the miss rate of polyps in a back-to-back colonoscopy study. Endoscopy. 2012 May;44(5):470-5. doi: 10.1055/s-0031-1291666. Epub 2012 Mar 22.
Results Reference
background
PubMed Identifier
8978338
Citation
Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997 Jan;112(1):24-8. doi: 10.1016/s0016-5085(97)70214-2.
Results Reference
background
PubMed Identifier
25512766
Citation
Pullens HJ, Siersema PD. Quality indicators for colonoscopy: Current insights and caveats. World J Gastrointest Endosc. 2014 Dec 16;6(12):571-83. doi: 10.4253/wjge.v6.i12.571.
Results Reference
background
PubMed Identifier
23744612
Citation
le Clercq CM, Bouwens MW, Rondagh EJ, Bakker CM, Keulen ET, de Ridder RJ, Winkens B, Masclee AA, Sanduleanu S. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut. 2014 Jun;63(6):957-63. doi: 10.1136/gutjnl-2013-304880. Epub 2013 Jun 6.
Results Reference
background
PubMed Identifier
20655393
Citation
Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol. 2010 Oct;8(10):858-64. doi: 10.1016/j.cgh.2010.06.028. Epub 2010 Jul 22.
Results Reference
background
PubMed Identifier
27920485
Citation
Chin M, Karnes W, Jamal MM, Lee JG, Lee R, Samarasena J, Bechtold ML, Nguyen DL. Use of the Endocuff during routine colonoscopy examination improves adenoma detection: A meta-analysis. World J Gastroenterol. 2016 Nov 21;22(43):9642-9649. doi: 10.3748/wjg.v22.i43.9642.
Results Reference
background
PubMed Identifier
29133257
Citation
Facciorusso A, Del Prete V, Buccino RV, Della Valle N, Nacchiero MC, Monica F, Cannizzaro R, Muscatiello N. Comparative Efficacy of Colonoscope Distal Attachment Devices in Increasing Rates of Adenoma Detection: A Network Meta-analysis. Clin Gastroenterol Hepatol. 2018 Aug;16(8):1209-1219.e9. doi: 10.1016/j.cgh.2017.11.007. Epub 2017 Nov 11.
Results Reference
background
PubMed Identifier
29698990
Citation
Williet N, Tournier Q, Vernet C, Dumas O, Rinaldi L, Roblin X, Phelip JM, Pioche M. Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials. Endoscopy. 2018 Sep;50(9):846-860. doi: 10.1055/a-0577-3500. Epub 2018 Apr 26.
Results Reference
background
PubMed Identifier
33524994
Citation
Zorzi M, Hassan C, Battagello J, Antonelli G, Pantalena M, Bulighin G, Alicante S, Meggiato T, Rosa-Rizzotto E, Iacopini F, Luigiano C, Monica F, Arrigoni A, Germana B, Valiante F, Mallardi B, Senore C, Grazzini G, Mantellini P; ItaVision Working Group. Adenoma detection by Endocuff-assisted versus standard colonoscopy in an organized screening program: the "ItaVision" randomized controlled trial. Endoscopy. 2022 Feb;54(2):138-147. doi: 10.1055/a-1379-6868. Epub 2021 Apr 8.
Results Reference
derived
Available IPD and Supporting Information:
Available IPD/Information Type
Analytic Code
Available IPD/Information URL
http://www.epiclin.it
Learn more about this trial
Adenoma Detection Rate With Endocuff-Assisted Colonoscopy - an Italian Trial
We'll reach out to this number within 24 hrs